Details for New Drug Application (NDA): 078671

NDA 078671 describes NABUMETONE, which is a drug marketed by Annora Pharma, Aurobindo Pharma Usa, Chartwell Molecules, Chartwell Rx, Copley Pharm, Epic Pharma Llc, Impax Labs Inc, Invagen Pharms, Lgm Pharma, Nostrum Labs Inc, Oxford Pharms, Sciegen Pharms Inc, and Watson Labs, and is included in thirteen NDAs. It is available from twenty-five suppliers. Additional details are available on the NABUMETONE profile page.

The generic ingredient in NABUMETONE is nabumetone. There are twenty drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the nabumetone profile page.

Summary for 078671

Tradename:	NABUMETONE
Applicant:	Invagen Pharms
Ingredient:	nabumetone
Patents:	0

Pharmacology for NDA: 078671

Mechanism of Action

Cyclooxygenase Inhibitors

Suppliers and Packaging for NDA: 078671

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
NABUMETONE	nabumetone	TABLET;ORAL	078671	ANDA	PD-Rx Pharmaceuticals, Inc.	43063-972	43063-972-20	20 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (43063-972-20)
NABUMETONE	nabumetone	TABLET;ORAL	078671	ANDA	PD-Rx Pharmaceuticals, Inc.	43063-972	43063-972-30	30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (43063-972-30)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	500MG
Approval Date:	Mar 7, 2008	TE:	AB	RLD:	No

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	750MG
Approval Date:	Mar 7, 2008	TE:	AB	RLD:	No

Complete Access Available with Subscription